Researchers from Yancheng Clinical College evaluated a comprehensive antimicrobial stewardship intervention targeting ICU patients with bloodstream infections. Between March 2022 and June 2023, the laboratory implemented an optimized workflow incorporating satellite blood culture incubation in the emergency department, upgraded culture bottles, rapid MALDI-TOF MS identification, automated rapid antimicrobial susceptibility testing (AST) reporting, and dual AST cards for Gram-negative bacteria. Comparing 153 post-optimization patients to 107 pre-optimization controls, results demonstrated that rapid AST reporting was 19.6 hours faster than conventional reporting. Total antibiotic duration decreased by 1.5 days, with significant reductions in broad-spectrum antibiotic usage, including meropenem and tigecycline. Hospital length of stay was reduced by five days. These findings underscore the substantial clinical and economic benefits of expedited diagnostic workflows in managing bloodstream infections, enabling faster pathogen identification and appropriate targeted antimicrobial therapy while reducing unnecessary broad-spectrum antibiotic exposure and healthcare costs.

UR Next Lab and Services Solutions, LLC addresses the clinical challenge of balancing diagnostic speed with accuracy in infectious disease testing. The company offers two complementary approaches: FDA-cleared, CLIA-waived Point-of-Care rapid diagnostics delivering results in ten to fifteen minutes, and Molecular RT-PCR/NAAT amplification panels for definitive diagnosis. Point-of-Care antigen tests employ monoclonal antibodies on nitrocellulose membranes or fluorescence cartridges to detect viral proteins or bacterial antigens from nasal or throat swabs, providing quick clinical guidance when symptoms are evident. Conversely, Reverse Transcription Polymerase Chain Reaction and Nucleic Acid Amplification Testing represent the gold standard for molecular diagnosis, directly amplifying pathogenic genetic material through thermal cycling. This approach exponentially multiplies viral RNA or DNA sequences—potentially generating over one billion copies from a single molecule within thirty-five to forty cycles—enabling detection of as few as one hundred to five hundred viral copies per milliliter. This superior sensitivity allows molecular testing to identify infections days before rapid tests become positive and maintains sensitivity throughout recovery, making it invaluable when early-stage symptoms are ambiguous or rapid tests yield false negatives despite clinical presentation.

Molecular diagnostics is undergoing a fundamental transformation from a specialized niche to core laboratory infrastructure, marking a shift from crisis-driven pandemic demand to sustainable, technology-anchored growth. The Indian molecular diagnostics market, valued at approximately ₹9,400 crore (USD 1 billion) in 2025, exemplifies this evolution. Characterized as reagent-heavy and PCR-anchored, it remains substantially import-dependent while expanding into genomics and oncology applications across smaller cities. The segment is transitioning from double-digit pandemic-era growth rates to projected compound annual growth of six to eight percent through the decade, reflecting a stabilization around infectious disease, oncology, and genetic testing rather than single-pathogen spikes. This structural shift is reshaping procurement economics, technology choices, and industry consolidation patterns. For diagnostic chains, hospital laboratories, and equipment suppliers, the strategic imperative has shifted from capacity expansion to optimizing workflows, capital allocation, and integrated reagent-driven infrastructure. The market's emphasis on reagents and consumables over analyzers underscores this transition, positioning reagent supply chains and workflow integration as competitive differentiators in the evolving molecular diagnostics landscape.

Bacterial antimicrobial resistance caused an estimated 1.27 million deaths in 2019, yet antimicrobial susceptibility testing (AST)—essential for guiding targeted therapy and stewardship—remains inaccessible in low-resource settings. Researchers from Hormuud University in Somalia conducted a narrative review of literature published between 2019 and 2026, searching PubMed, Scopus, and Google Scholar for studies addressing economic barriers to AST implementation in low- and middle-income countries. The analysis identified three interconnected levels of economic obstruction: patient-level barriers including out-of-pocket costs and transportation; laboratory-level constraints such as infrastructure deficits, reagent shortages, and insufficient workforce; and health-system-level underinvestment coupled with donor dependency. These barriers perpetuate broad-spectrum empirical prescribing, amplifying selection pressure and driving emergence of resistant organisms including methicillin-resistant Staphylococcus aureus, extended-spectrum β-lactamase-producing Enterobacterales, and carbapenem-resistant pathogens. Consequences extend beyond treatment failure to catastrophic household expenditures and threats to universal health coverage. The authors recommend subsidized diagnostics, insurance coverage for microbiology services, tiered laboratory strengthening, and integrated diagnostic and antimicrobial stewardship programs as essential responses to scale AST accessibility and combat resistance.

AmplexDiagnostics and Scope Biosciences have announced eazySNP, an innovative molecular diagnostic technology that combines LAMP and CRISPR methodologies to enable rapid and highly specific detection of genetic variants. The collaboration represents a significant advancement in molecular SNP diagnostics. The first CE-IVD certified product, eazySNP C. auris FKS1 S639, targets Candidozyma auris, a multidrug-resistant yeast pathogen of major clinical concern. This assay rapidly identifies echinocandin-resistance mutations in the FKS1 gene—critical for treatment planning since echinocandins are the first-line therapy for C. auris infections. Performed directly from yeast colonies using the eazyMini platform, results are delivered within 45 minutes, providing laboratories with the first rapid molecular solution for detecting this clinically important resistance marker. For Scope Biosciences, this launch marks a strategic expansion from plant health diagnostics into human molecular diagnostics, demonstrating the commercial viability of their CRISPR technology platform.

“La nouvelle Steve Jobs”. En septembre 2015, le magazine Inc. consacre sa couverture et un portrait dithyrambique à Elizabeth Holmes. Personne ne le sait encore, mais ce sont les derniers instants de gloire pour la fondatrice de Theranos, devenue alors, à 31 ans, la plus jeune milliardaire non héritière au monde. Le 16 octobre, le château de cartes qu’elle a bâti pendant onze ans commence à s’effondrer, à la suite de la publication d’une enquête dévastatrice du Wall Street Journal. Malgré les dénégations, ces révélations emporteront tout sur leur passage, précipitant la chute de l’entrepreneuse et la conduisant jusqu’en prison.

Advanced diagnostics determine over 70% of clinical decisions yet receive only 2% of global healthcare spending, creating a critical gap in health equity—particularly in Asia-Pacific. The region faces disproportionate disease burdens, accounting for 62.6% of global liver disease deaths, 60% of tuberculosis cases, and nearly half of global breast cancer diagnoses, compounded by rapid population ageing projected to increase significantly by 2050. This diagnostic underinvestment has serious consequences: missed or imprecise diagnoses cannot always be corrected later, even with advanced therapies, affecting critical applications like immunosuppressive drug dosing post-transplant. Technological innovations, particularly automated mass spectrometry, are transforming access to precision diagnostics in routine clinical settings across Asia-Pacific. By enabling high-specificity molecular detection without requiring specialized laboratory facilities, these scalable technologies make precision care accessible where it's needed most. Expanding diagnostic capabilities in the region is essential to manage rising chronic disease burdens and address the current undervaluation of diagnostics by both medical professionals and policymakers globally.

The United States recorded 6,304 new clinical cases of Candida auris in 2024, continuing an upward trajectory since the fungus's first U.S. detection in 2016, though the rate of increase has recently slowed. C. auris cases are identified through clinical samples from invasive sites like blood or cerebrospinal fluid, or non-invasive sites such as urine and wounds, with screening cases detected through colonization swabs. While transmission persists in certain geographic areas and has expanded into new regions, recommended infection prevention and control practices have successfully contained outbreaks in some locations when implemented early. The CDC, collaborating with state and local health departments, diagnostic laboratories, and healthcare facilities, tracks cases reported through standardized Council of State and Territorial Epidemiologists definitions and provides support via its Antimicrobial Resistance Lab Network. Proactive case detection, patient screening, and rigorous adherence to infection control protocols remain critical for preventing healthcare facility outbreaks and limiting this emerging threat's spread.

Researchers have developed a rapid diagnostic approach for identifying pathogenic microorganisms directly from positive blood cultures and simultaneously determining their antimicrobial susceptibility profiles. Published in PLOS One by Xu and colleagues, this study addresses a critical clinical challenge in sepsis management, where timely identification of bloodstream pathogens and their resistance patterns is essential for appropriate antibiotic selection. Traditional methods require lengthy culture periods, delaying treatment decisions and potentially compromising patient outcomes. The research presents an expedited testing methodology that significantly reduces the time-to-result for both pathogen identification and susceptibility testing from positive blood culture samples. By enabling faster diagnosis and resistance profiling, this approach allows clinicians to implement targeted antimicrobial therapy more rapidly, potentially improving treatment efficacy and reducing inappropriate antibiotic use. The innovation holds substantial value for intensive care settings and clinical microbiology laboratories, where rapid turnaround times directly impact patient prognosis in life-threatening bloodstream infections.

Point-of-care CRISPR-based diagnostics represent a transformative approach to molecular testing that combines laboratory precision with rapid, decentralized deployment. While traditional CRISPR platforms utilize intact guide RNA and single Cas effector proteins, they frequently suffer from background signal leakage, off-target activation, and complex sample preparation. Bioengineers have developed split molecular systems that address these limitations by dividing essential CRISPR components into inactive fragments that remain non-functional until a target sequence appears in the sample. Upon target hybridization, these fragments spontaneously assemble into an active Cas complex that initiates collateral cleavage of reporter molecules. This conditional mechanism dramatically suppresses baseline noise while enabling extraordinary diagnostic fidelity. The split crRNA architecture divides the guide RNA into multiple inactive fragments that cannot independently activate Cas endonucleases. When a specific complementary target sequence is introduced, rapid hybridization triggers reassembly of a complete, catalytically functional guide RNA. This dual-recognition system suppresses spurious enzymatic activation and prevents accidental off-target cleavage from mismatched sequences. By fine-tuning thermodynamic hybridization properties of each fragment, assay designers achieve single-base discrimination, enabling reliable differentiation of viral variants and drug-resistant bacterial strains. This split system approach establishes a dependable foundation for high-precision molecular detection in primary care settings without requiring expensive laboratory infrastructure.

Molecular public health represents an emerging paradigm that integrates molecular epidemiology with public health practice to enhance infectious disease prevention and surveillance. This comprehensive review examines the conceptual framework and technological infrastructure underpinning this integrated approach. Key components include bioinformatics and data integration systems that serve as interpretive engines for molecular datasets, alongside molecular detection and quantification technologies that enable precise pathogen identification. The review emphasizes next-generation sequencing for pathogen genomic surveillance, genomic epidemiology and phylodynamics for tracking disease transmission, and metagenomics for pathogen-agnostic surveillance capabilities. Novel applications include wastewater and environmental surveillance for early disease detection, One Health molecular surveillance coordinating human-animal-environmental monitoring, and molecular approaches to antimicrobial resistance tracking. Advanced techniques such as multi-omics analysis and host-response surveillance provide deeper biological insights, while artificial intelligence and computational public health optimize data interpretation and predictive modeling. Together, these technologies create a sophisticated surveillance ecosystem that enables real-time pathogen monitoring, rapid outbreak detection, and evidence-based public health interventions for emerging and re-emerging infectious diseases.

Matrix-Assisted Laser Desorption Ionization Time-Of-Flight (MALDI-TOF) mass spectrometry has emerged as a transformative technology for rapid microbial identification across clinical, environmental, and industrial applications. Recent research demonstrates the integration of MALDI-TOF with artificial intelligence significantly enhances bacterial and viral pathogen classification accuracy and speed, addressing critical needs in clinical diagnostics and biodefense. Notable developments include IDBac, an open-access web platform enabling bacteria identification and relationship analysis using MALDI-TOF mass spectrometry, published in Nature Communications. Comparative studies reveal performance differences between systems, including the Bruker Microflex LT Biotyper and the newer Zybio EXS2600 Ex-Accuspec, tested on 1,130 milk bacterial isolates. The technology demonstrates particular value in detecting antibiotic resistance in Burkholderia pseudomallei and identifying microbial contamination in diesel fuels. These advances matter significantly because rapid, accurate pathogen identification enables faster clinical interventions, supports public health surveillance for antibiotic-resistant organisms, and protects fuel system integrity and operational safety across diverse sectors.

Horizon Europe Cluster 6 is launching funding opportunities for 2026-2027 addressing critical challenges in food security, biodiversity conservation, land management, and bioeconomy development. The call calendar opens between January and August 2026, with subsequent openings in February and April 2027, featuring deadlines spanning April through September 2026 and extending into May 2027. A microfluidic technology specialist has analyzed the cluster's work programme to identify calls with significant relevance to microfluidic applications. Key opportunities with highest microfluidic relevance include commercializing food systems microbiome solutions, integrating holistic microbiome research for sustainable food systems, assessing groundwater ecosystem functions, decontaminating and bioremediation of aquatic pollution, advancing European bio-based innovation through biotechnology and biomanufacturing, developing microbiome applications for livestock sustainability, and implementing advanced solutions for controlled environment agriculture. The analysis ranks microfluidic relevance from fifty to one hundred percent across eligible topics. This strategic assessment enables SMEs and research organizations to identify optimal funding opportunities aligned with microfluidic engineering capabilities and innovation potential within European agricultural and environmental priorities.

The COVID-19 pandemic exposed critical diagnostic testing gaps, with laboratories overwhelmed by high sample volumes, delayed results, and compromised disease control. While existing point-of-care testing devices lack sensitivity and molecular tests like PCR demand complex infrastructure and trained personnel, contamination risks further limit decentralized testing. This patent introduces an innovative, fully integrated microfluidic device for nucleic acid molecular point-of-care testing that operates on a "sample-in, result-out" workflow without requiring laboratory settings or specialized training. The disposable device comprises three components: a sample tube with buffer, a microfluidic reaction tube pre-loaded with dried amplification reagents, and a readout cartridge. Its closed-system design prevents contamination through sealed connections, while capillary-driven fluidics and thermally activated valves control liquid transfer. A puncture mechanism releases amplified products onto a lateral flow assay strip for colorimetric detection. By eliminating manual steps like pipetting and centrifugation and employing isothermal amplification such as LAMP, the device enables rapid, equipment-free nucleic acid detection. This innovation addresses the urgent need for portable, user-friendly, contamination-proof molecular diagnostics accessible in non-laboratory environments.

Researchers have developed a CRISPR/Cas-based diagnostic approach for detecting Klebsiella pneumoniae, a clinically significant pathogen responsible for serious infections worldwide. The study, authored by Yi, Luo, and colleagues and published in Frontiers in Bioengineering and Biotechnology, addresses the dual threat posed by carbapenem-resistant K. pneumoniae (CRKP) and hypervirulent K. pneumoniae (hvKp) strains. The diagnostic platform targets both antimicrobial resistance-associated markers and hypervirulence-associated markers, enabling rapid and accurate identification of pathogenic variants. This advancement translates molecular detection capabilities into clinically interpretable risk reporting, facilitating more informed clinical decision-making and patient management strategies. By combining CRISPR/Cas technology with comprehensive marker analysis, the approach offers healthcare providers actionable intelligence about infection severity and treatment options, potentially improving outcomes in cases of K. pneumoniae infection while supporting antimicrobial stewardship efforts in clinical settings.

The FDA has cleared a multiplex PCR test capable of simultaneously detecting 13 different respiratory pathogens, addressing a significant clinical challenge in infectious disease diagnosis. Respiratory tract infections present a diagnostic dilemma because numerous causative agents produce overlapping, nonspecific symptoms that clinicians initially classify as influenza-like illnesses. This multiplex approach enables rapid, comprehensive pathogen identification from a single patient sample, improving diagnostic accuracy and potentially streamlining treatment decisions. By distinguishing between multiple viral and bacterial respiratory agents in one test, clinicians can better differentiate between conditions requiring different therapeutic interventions and infection control measures. The technology represents an advancement in molecular diagnostics, allowing healthcare providers to move beyond empirical treatment protocols toward targeted antimicrobial therapy based on confirmed pathogen identification. This development enhances clinical efficiency and supports appropriate antibiotic stewardship by reducing unnecessary prescriptions for patients with viral infections, while accelerating care for those requiring specific antimicrobial therapy.

Organ-on-a-Chip (OoC) systems represent a transformative approach to in vitro diagnostics, integrating microfluidic engineering, 3D tissue construction, and sensing technologies to recreate human organ functionality with unprecedented physiological relevance. This comprehensive review from Chongqing Three Gorges Medical College examines how OoC platforms address critical limitations of traditional 2D cell cultures and animal models, which contribute to the 90% failure rate of candidate drugs and biomarkers during clinical translation. The article systematically covers core construction technologies including microfluidic regulation, cell and tissue engineering, and material innovation, alongside dual-detection systems combining real-time online monitoring with offline analysis. Key applications span disease modeling, biomarker screening, drug toxicity evaluation, and personalized diagnosis. The review also explores Multi-Organ-Chip systems enhanced by Artificial Intelligence integration while identifying significant bottlenecks: insufficient physiological complexity, standardization gaps, and clinical translation barriers. By establishing theoretical frameworks and practical guidance for transitioning OoC from research laboratories to clinical tools, this work emphasizes the urgent need for technological optimization, standardization protocols, and regulatory pathway development to realize OoC's potential in improving drug development efficiency and diagnostic accuracy.

West Nile virus (WNV) represents the most common domestic arboviral infection in the contiguous United States, yet current surveillance methods remain fragmented and incomplete. Existing surveillance approaches—including mosquito monitoring, dead bird tracking, and human testing—are inconsistently applied nationwide and often miss mild or asymptomatic infections. Researchers assessed wastewater surveillance as a supplementary tool for comprehensive WNV tracking by testing archived RNA and raw wastewater samples from six states during the 2023 transmission season. The study detected WNV RNA in 18 percent of samples across Arizona, California, Colorado, Illinois, Indiana, and Nebraska. These findings demonstrate wastewater surveillance's capability to identify WNV circulation in communities, including cases that traditional surveillance methods would overlook. Since no approved vaccines or therapeutics for WNV currently exist, and severe neuroinvasive disease affects less than one percent of infected individuals while approximately 1,300 neuroinvasive cases occur annually, enhanced surveillance systems are critical. Wastewater surveillance offers significant potential to augment existing WNV monitoring infrastructure and provide earlier detection of viral circulation patterns, enabling more timely public health interventions.

Infectious disease management is increasingly adopting precision approaches where antimicrobial therapy selection, timing, and dosing are guided by diagnostic findings about pathogen characteristics, host response, and drug action mechanisms. Diagnostic-guided antimicrobial stewardship has emerged as a critical strategy to combat antimicrobial resistance (AMR) by enabling clinicians to target treatment to the specific biology of an infection rather than relying on empirical approaches. However, realizing this potential requires bridging two often-disconnected levels of evidence: the microbiological and immunological basis of diagnostic tests—including which resistance mechanisms, virulence factors, and host-response signatures they detect and how reliably these map to treatment outcomes—and their clinical performance in real-world settings. Recent experiences from the COVID-19 pandemic and ongoing AMR containment efforts demonstrate that diagnostic capability frequently becomes the rate-limiting factor in infectious disease response. To address this gap, a comprehensive research initiative brings together microbiologists, immunologists, infectious disease clinicians, and diagnostics researchers to establish an evidence base linking pathogen and host biology to diagnostic-guided antimicrobial decision-making. Key research areas include identifying biomarkers for resistance detection, validating host-response signatures that distinguish infection types, and developing rapid point-of-care diagnostics suitable for resource-limited settings, ultimately transforming promising markers into practical stewardship tools.

Researchers have developed a novel CRISPR-Cas13-based diagnostic platform for rapid detection of three quarantine-significant sugarcane viruses without requiring nucleic acid amplification. This amplification-free approach represents a significant advancement over traditional PCR-based methods, offering faster results and simplified workflows. The technique leverages the specificity of Cas13 proteins to identify viral RNA sequences directly, providing a more efficient diagnostic solution. The study, published in Plant Cell Reports in September 2026, demonstrates the feasibility of this molecular detection strategy for plant virology applications. By eliminating amplification steps, the method reduces processing time and complexity while maintaining detection accuracy for viruses of quarantine importance in sugarcane cultivation. This advancement has implications for improving disease surveillance and quarantine protocols in agricultural settings, enabling faster identification of infected plants to prevent viral spread. The amplification-free CRISPR-Cas13 platform could serve as a foundation for developing portable, field-deployable diagnostic tools for plant disease management.